The presented mechanism of enhancement of the WT1TCR signaling by NFAT-regulated CAR can be modified to target different WT1-positive tumors, such as ovarian and lung carcinoma, by using inducible CAR specific to surface antigens such as mesothelin, Her2, or folate receptor alpha. This evidence concerns the gene FOLR1 and lung carcinoma.